Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Published
  • Abstracts highlight the serious clinical burden of uncontrolled NASH and identify opportunities to improve patient care
  • In an analysis of patient records from a large claims database, the risk of progressing to cirrhosis, decompensated cirrhosis, liver transplant, or all-cause death increased from 10.5% after one year to 31.4% after 5 years in patients with noncirrhotic NASH

CONSHOHOCKEN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced five health economics abstracts being presented at the NASH-TAG Conference, taking place from January 4-6, 2024 in Park City, Utah.

Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases. The abstracts being presented at NASH-TAG underscore the relationship between NASH progression and adverse patient outcomes, reinforce previous evidence suggesting NASH independently contributes to cardiovascular risk, and indicate that many patients with NASH are not being monitored at the frequency recommended by clinical guidelines. These analyses also suggest opportunities to improve care through noninvasive testing strategies and a more holistic approach to assessing cardiovascular risk in patients with NASH.”

Bill Sibold, Chief Executive Officer of Madrigal, stated, “Madrigal’s health economics outcomes research efforts are part of a long-term strategy to provide healthcare decision-makers with data and insights to improve patient care and contextualize the potential value of resmetirom as a foundational therapy for patients with NASH. The serious burden of uncontrolled NASH on patients and the health system is coming into focus: as the disease progresses to cirrhosis, patients face markedly elevated risk of liver-related and cardiovascular outcomes. This is why it is essential to treat NASH with significant fibrosis before patients progress to cirrhosis.”

A summary of the health economics outcomes research abstracts being presented at NASH-TAG follows:

Abstract #21: “Non-invasive tests as a prediction tool to assess MASH resolution score” [Presenter: Jesse Fishman]In an evaluation of biopsy and noninvasive test data from patients included in the TARGET-NASH registry, the FibroScan-AST score (FAST), FibroScan vibration-controlled transient elastography (VCTE), and the aspartate aminotransferase-to-platelet ratio index (APRI) demonstrated a strong ability to predict NASH resolution. Overall, patients without NASH resolution had larger baseline median FIB-4 (1.7 vs. 1.4, p

In This Story

MDGL